Adlai Nortye Ltd. to Post FY2024 Earnings of ($0.88) Per Share, HC Wainwright Forecasts (NASDAQ:ANL)

Adlai Nortye Ltd. (NASDAQ:ANL) – Stock analysts at HC Wainwright issued their FY2024 EPS estimates for shares of Adlai Nortye in a report issued on Wednesday, September 4th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.88) per share for the year. HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Adlai Nortye’s current full-year earnings is ($2.37) per share. HC Wainwright also issued estimates for Adlai Nortye’s FY2025 earnings at ($0.92) EPS and FY2026 earnings at ($0.99) EPS.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Adlai Nortye in a research note on Thursday, June 20th.

Adlai Nortye Stock Performance

ANL opened at $2.20 on Friday. The stock has a fifty day moving average of $3.18 and a 200-day moving average of $7.00. Adlai Nortye has a 12-month low of $2.20 and a 12-month high of $19.30.

Institutional Trading of Adlai Nortye

An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. lifted its position in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 40,310 shares of the company’s stock after buying an additional 22,644 shares during the quarter. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 as of its most recent filing with the SEC. 35.21% of the stock is owned by hedge funds and other institutional investors.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.